Can “At Risk” Disease Phenotypes Prioritize Earlier Treatment (EVOLVED)

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker's Bureau - Novartis; AstraZenca; Silence Therapeutics; Bristol-Myers Squibb; Pfizer